⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11311069 | 0.82 | — | — | |
| SCHEMBL11220859 | 0.82 | — | — | |
| SCHEMBL29389890 | 0.71 | — | — | |
| SCHEMBL29512245 | 0.71 | — | — | |
| SCHEMBL29377526 | 0.71 | — | — | |
| Methane SCHEMBL28750057 | 0.71 | — | — | |
| SCHEMBL29715907 | 0.71 | — | — | |
| SCHEMBL30905106 | 0.71 | — | — | |
| SCHEMBL21418 | 0.71 | — | — | |
| SCHEMBL2266230 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240423967-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2024-12-26 | — | — | US | disclosed |
| US-12083107-B2 | Pharmaceutical compositions comprising glitazones and Nrf2 activators | Kahrs, Bjoern Colin (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-2793876-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | KAHRS BJOERN COLIN (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | KAHRS, Bjoern Colin (CH) | 2023-06-22 | — | — | US | disclosed |
| US-11484530-B2 | Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators | Kahrs, Bjoern Colin (CH) | 2022-11-01 | — | — | US | disclosed |
| US-20220166014-A1 | SURFACE TREATMENT SOLUTION, METHOD FOR PREPARING SURFACE TREATMENT SOLUTION, METHOD FOR PREPARING ACTIVE MATERIAL USING SURFACE TREATMENT SOLUTION, AND ACTIVE MATERIAL PREPARED THEREBY | HYUNDAI MOTOR COMPANY (KR) | 2022-05-26 | — | — | US | disclosed |
| US-10426763-B2 | Pharmaceutical compositions comprising glitazones and NRF2 activators | Kahrs, Bjoern Colin (CH) | 2019-10-01 | — | — | US | disclosed |
| US-20170065571-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2017-03-09 | — | — | US | disclosed |
| CN-106457237-A | Methods for reprocessing used catalysts | 托品能企业有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9504679-B2 | Pharmaceutical compositions comprising glitazones and Nrf2 activators | Kahrs, Bjoern Colin (CH) | 2016-11-29 | — | — | US | disclosed |
| WO-2016074684-A1 | FUMARIC ACID DERIVATIVES FOR MEDICAL USE | SYDDANSK UNIVERSITET (DK) | 2016-05-19 | — | — | WO | disclosed |
| US-8524773-B2 | Utilization of dialkylfumarates | BIOGEN IDEC INTERNATIONAL GMBH (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20130004526-A1 | Utilization of Dialkylfumarates | BIOGEN IDEC INTERNATIONAL GMBH (CH) | 2013-01-03 | — | — | US | disclosed |
| US-6436992-B1 | ADMINISTERING MONO/DIALKYL ESTER METAL SALTS, FOR PROPHYLAXIS OF AUTOIMMUNE DISEASES, SELECTED FROM GRAFT-VERSUS HOST/GRAVE'S DISEASE, DIABETES, THYROIDS, SJOGREN'S SYNDROME, PERNICIOUS ANAEMIA, MULTIPLE SCLEROSIS OR HEPATITIS | FUMAPHARM AG (CH) | 2002-08-20 | — | — | US | disclosed |
| US-5424332-A | For treating psoriasis and psoriatic arthritis; using fumaric acid monoalkylester calcium, iron or magnesium salt | SPEISER PETER P (CH) | 1995-06-13 | — | — | US | disclosed |
| US-4959389-A | MONOALKYL FUMARATE SALTS, DIALKYL FUMARATES | SPEISER PETER P (CH) | 1990-09-25 | — | — | US | disclosed |